Any current/future new fundraising through debt or equity?

Navin Fluorine International Limited plans two new capital expenditures (capex) totaling INR 372 crores. These include INR 288 crores for setting up a cGMP4 facility and INR 84 crores to enhance HFC capacity. Both capex projects will be fully funded through internal accruals. There is no mention of any current or future fundraising through debt or equity in the provided pages. The company maintains a tight financial framework and focuses on funding growth through internal resources.

Any current/future capex/capital investment/strategic investment?

INR 372 crores capex approved, funded through internal accruals. INR 288 crores for setting up a cGMP4 facility (capacity: 200 KL) in phases. - Phase 1 with 100 KL capacity costing INR 160 crores, expected commissioning by end of CY '25. - Phase 2 will be initiated based on MSA progress and business projections. INR 84 crores capex to enhance HFC capacity, adding 4,500 tons of R32 refrigerant gas, operational by Feb '25. Agro specialty plant at Dahej progressing well; chemical charge expected by Mar/Apr 2024; first commercial supply by end Q1 FY '25. AHF project at Dahej progressing as per

Future growth expectations in sales/revenue/volumes?

Specialty Chemicals: Expect recovery and growth in FY '25 with addition of 3-4 new molecules and return of deferred campaigns, leading to higher volumes and revenues. Multipurpose plant (MPP1) targets 80% peak revenue utilization in FY '24; dedicated agro specialty plant to contribute from Q1 FY '25. CDMO Business: Business is lumpy; expect stable revenues with higher-margin early- and commercial-stage products. Targeting $100 million revenue by FY '27 with expansion via cGMP4 facility expected from H2 FY '25. HFO Plant: Ramp-up challenges being addressed; expect peak revenues of INR 460 cro

Future growth expectations in earnings/operating earnings/profits/EPS?

Specialty Chemicals base business expected to recover in FY '25, with addition of 3 new molecules contributing from that year onwards. CDMO business aims to reach $100 million revenue by FY '27, supported by new cGMP4 facility (Phase 1 commissioning by end CY '25). HFO plant expected to achieve peak annual revenue (~INR 460 crores) in FY '25, normalizing ramp-up challenges. EBITDA margins expected to rebound to 24-25% range as market conditions improve and one-off costs recouped. New capex of INR 372 crores funded through internal accruals aimed at capacity expansion and technology advancement

Current/ Expected Orderbook/ Pending Orders?

The CDMO business order book experienced some deferrals, with key campaigns from the last fiscal delayed but expected to return in FY '25. A $16 million purchase order from an American company, initially expected earlier, has been deferred to Q4 of the current fiscal. The firm has expanded the MSA with a European-based API customer to cover 3 molecules, expected to contribute materially to CDMO revenues from FY '26 onwards. Strategic partnership with a U.S.-based CDMO is expected to open additional commercial opportunities starting H2 FY '25. Specialty chemicals base business saw decline due t

Navin Fluo.Intl.Q3 FY24

Navin Fluo.Intl. Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹8,352P/E: 52.5Market Cap: ₹41.8K Cr

Management growth scorecard

Revenue

Category 3

Margin

Category 2

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

Specialty Chemicals: Expect recovery and growth in FY '25 with addition of 3-4 new molecules and return of deferred campaigns, leading to higher volumes and revenues. Multipurpose plant (MPP1) targets 80% peak revenue utilization in FY '24; dedicated agro specialty plant to contribute from Q1 FY '25.
CDMO Business: Business is lumpy; expect stable revenues with higher-margin early- and commercial-stage products. Targeting $100 million revenue by FY '27 with expansion via cGMP4 facility expected from H2 FY '25.
HFO Plant: Ramp-up challenges being addressed; expect peak revenues of INR 460 crores in FY '25 with volume growth as demand normalizes.
R32 Refrigerant: Current capacity fully utilized; demand expected to grow significantly post-2026 with quota restrictions, leading to tight supply and pricing support from 2028 onward.
Overall, gradual recovery expected in FY '25 with stronger momentum in second half driven by specialty chemicals, CDMO expansion, and refrigerant demand.

Margin guidance

Category 2

Specialty Chemicals base business expected to recover in FY '25, with addition of 3 new molecules contributing from that year onwards.
CDMO business aims to reach $100 million revenue by FY '27, supported by new cGMP4 facility (Phase 1 commissioning by end CY '25).
HFO plant expected to achieve peak annual revenue (~INR 460 crores) in FY '25, normalizing ramp-up challenges.
EBITDA margins expected to rebound to 24-25% range as market conditions improve and one-off costs recouped.
New capex of INR 372 crores funded through internal accruals aimed at capacity expansion and technology advancement.
Strategic partnerships (European API customer expansion, US-based CDMO) projected to boost CDMO revenues materially from FY '26 onwards.
Overall mid- to long-term growth outlook remains intact, with operational excellence and innovation focus positioning Navin Fluorine for future earnings growth.

See what Navin Fluo.Intl. management said on margin guidance — free account, 30 seconds.

Fundraise plans

Navin Fluorine International Limited plans two new capital expenditures (capex) totaling INR 372 crores.
These include INR 288 crores for setting up a cGMP4 facility and INR 84 crores to enhance HFC capacity.
Both capex projects will be fully funded through internal accruals.
There is no mention of any current or future fundraising through debt or equity in the provided pages.
The company maintains a tight financial framework and focuses on funding growth through internal resources.

Order book

The CDMO business order book experienced some deferrals, with key campaigns from the last fiscal delayed but expected to return in FY '25.
A $16 million purchase order from an American company, initially expected earlier, has been deferred to Q4 of the current fiscal.
The firm has expanded the MSA with a European-based API customer to cover 3 molecules, expected to contribute materially to CDMO revenues from FY '26 onwards.
Strategic partnership with a U.S.-based CDMO is expected to open additional commercial opportunities starting H2 FY '25.
Specialty chemicals base business saw decline due to campaign deferments and inventory destocking; 4 new molecules are in the pipeline, expected to come into play by end of Q4.
The company has full visibility to a stronger Q4 and expects recovery in specialty chemicals and CDMO segments in FY '25.

See what Navin Fluo.Intl. management said on order book — free account, 30 seconds.

Capex plans

Yes

INR 372 crores capex approved, funded through internal accruals.
INR 288 crores for setting up a cGMP4 facility (capacity: 200 KL) in phases.
- Phase 1 with 100 KL capacity costing INR 160 crores, expected commissioning by end of CY '25.
- Phase 2 will be initiated based on MSA progress and business projections.
INR 84 crores capex to enhance HFC capacity, adding 4,500 tons of R32 refrigerant gas, operational by Feb '25.
Agro specialty plant at Dahej progressing well; chemical charge expected by Mar/Apr 2024; first commercial supply by end Q1 FY '25.
AHF project at Dahej progressing as per schedule.
INR 30 crores capex to develop a completely new capability in Surat, expected to generate revenue from FY '25.
Strategic partnership with a U.S.-based CDMO to expand capabilities and customer base.

Track Navin Fluo.Intl. — get its next earnings analysis in your feed

How does Navin Fluo.Intl. rank vs peers in ?

Pro feature

ThisNavin Fluo.Intl.

Rev 3Mar 2

See where Navin Fluo.Intl. sits in See which companies these are, and every other name in the sector.Open rankings

What Navin Fluo.Intl.'s management said in earlier quarters

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →